Life expectancy living with HIV: Recent estimates and future implications

Current Opinion in Infectious Diseases

Volumn 26, Issue 1, 2013, Pages 17-25

  Nakagawa, Fumiyo ^a   May, Margaret ^b   Phillips, Andrew ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

antiretroviral therapy; HIV; life expectancy

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CEPAC MODEL; CLINICAL RESEARCH; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIFE EXPECTANCY; LIFESPAN; MATHEMATICAL MODEL; MONTE CARLO METHOD; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SEROLOGY; SMOKING; SURVIVAL RATE; TREATMENT DURATION; UNITED STATES;

ANTI-RETROVIRAL AGENTS; COHORT STUDIES; EARLY DIAGNOSIS; FORECASTING; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; LIFE EXPECTANCY; MODELS, THEORETICAL;

EID: 84871746299     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835ba6b1     Document Type: Review

References (75)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Together we will end AIDS. Geneva: UNAIDS; 2012. http://www.unaids.org/en/resources/campaigns/ togetherwewillendaids/unaidsreport/. [Accessed 10 August 2012]
2. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113:91-98. (Pubitemid 34804744)
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
4. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29. (Pubitemid 36835816)
5. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671. (Pubitemid 34921112)
6. The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
7. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805. (Pubitemid 40693195)
8. Bonnet F, Morlat P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3:195-199.
9. Van Sighem A, Gras L, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24:1527-1535.
10. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335-343.
11. Porta M. A dictionary of epidemiology. 5th ed. New York, NY: Oxford University Press. 2008.
12. Chiang CL. The life table and its applications. Malabar (Florida): Robert E Krieger Publishing Company; 1984.
13. Anderson RM, Medley GF. Epidemiology of HIV infection and AIDS: incubation and infectious periods, survival and vertical transmission. AIDS 1988; 2:S57-S63. (Pubitemid 19042839)
14. Lifson AR, Hessol NA, Rutherford GW. Progression and clinical outcome of infection due to human immunodeficiency virus. Clin Infect Dis 1992; 14:966-972.
15. Collaborative Group on AIDS Incubation and HIV Survival and including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355:1131-1137.
16. Nicoll A, Gill ON. The global impact of HIV infection and disease. Commun Dis Public Health 1999; 2:85-95.
17. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831. (Pubitemid 32222162)
18. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19.
19. Wood E, Low-Beer S, Bartholomew K, et al. Modern antiretroviral therapy improves life expectancy of gay and bisexual males in Vancouver's west end. Can J Public Health 2000; 91:125-128. (Pubitemid 30364800)
20. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685-692. (Pubitemid 46568625)
21. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
22. Lohse N, Hansen ABE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95. (Pubitemid 351640011)
23. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multidrug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15:2379-2384. (Pubitemid 34014606)
24. Matthews GV, Sabin C, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61. (Pubitemid 34062182)
25. Moore RD, Keruly JC. CD4\+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-446. (Pubitemid 46147630)
26. Piroth L, Fournel I, Mahy S, et al. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients. Epidemiol Infect 2011; 139:1835-1844.
27. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:209-216.
28. Harrison KM, Song RG, Zhang XJ. Life expectancy after HIV diagnosis based on National HIV Surveillance data from 25 States, United States. J Acquir Immune Defic Syndr 2010; 53:124-130.
29. Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 2012; 26:45-56.
30. May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343:d6016.
31. Braithwaite RS, Roberts MS, Goetz MB, et al. Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis 2009; 48:822-826.
32. Bakanda C, Birungi J, Mwesigwa R, et al. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS 2011; 25:701-705.
33. Bakanda C, Birungi J,Mwesigwa R, et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One 2011; 6:e19261.
34. Bor J, Herbst AJ, Newell ML, Barnighausen T. Dramatic increases in population life expectancy and the economic value of ART in rural South Africa. 19th International Conference on AIDS; 22nd-27th July 2012; Washington, DC;
35. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49:1570-1578.
36. Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504-1513.
37. Braithwaite RS, Fiellin DA, Nucifora K, et al. Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value? Value Health 2010; 13:535-542.
38. Roberts MS, Nucifora KA, Braithwaite RS. Using mechanistic models to simulate comparative effectiveness trials of therapy and to estimate long-term outcomes in HIV care. Med Care 2010; 48:S90-S95.
39. Braithwaite RS, Roberts MS, Chang CCH, et al. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med 2008; 148:178-185. (Pubitemid 351665505)
40. Bansi L, Sabin C, Delpech V, et al. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med 2010; 11:432-438.
41. Phillips AN, Sabin C, Pillay D, Lundgren JD. HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med 2007; 8:536-546. (Pubitemid 47616833)
42. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science 2002; 296:1029-1031.
43. Leon DA. Trends in European life expectancy: a salutary view. Int J Epidemiol 2011; 40:271-277.
44. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalite 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
45. Palella FJJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
46. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
47. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-2418.
48. Frisch M, Biggar RJ, Engels EA, Goedert JJ, for the AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-1745. (Pubitemid 32259908)
49. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453. (Pubitemid 46594077)
50. Maggi P, Quirino T, Ricci E, et al. Cardiovascular risk assessment in antiretroviral-naive HIV patients. AIDS Patient Care STDS 2009; 23:809-813.
51. Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not shortterm HAART, induces endothelial dysfunction. AIDS 2009; 23:589-596.
52. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2012; doi:10.1177/1740774512440342. [Epub ahead of print]
53. Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). Int J STD AIDS 2008; 19:297-304. (Pubitemid 351748269)
54. Mills EJ, Barnighausen T, Negin J. HIV and aging-preparing for the challenges ahead. N Engl J Med 2012; 366:1270-1273.
55. Effros RB, Fletcher C, Gebo K, et al. Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542-553.
56. Oursler KK, Goulet JL, Crystal S, et al. Association of age and comorbidity with physical function in HIV-infected and uninfected patients: results from the Veterans Aging Cohort Study. AIDS Patient Care STDS 2011; 25:13-20.
57. Health Protection Agency. HIV in the United Kingdom: 2011 Report. London: Health Protection Services, Colindale; November 2011. http://www.hpa. org.uk/webc/HPAwebFile/HPAweb-C/1317131685847. [Accessed 10 August 2012]
58. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144. (Pubitemid 351590049)
59. Hughes MD, Ribaudo HR. The search for data on when to start treatment for HIV infection. J Infect Dis 2008; 197:1084-1086. (Pubitemid 351590042)
60. Stohr W, Dunn DT, Porter K, et al. CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Med 2007; 8:135-141. (Pubitemid 46915683)
61. Lucas SB, Curtis H, Johnson MA. National review of deaths among HIVinfected adults. Clin Med 2008; 8:250-252. (Pubitemid 351960975)
62. Lloyd-Smith E, Brodkin E, Wood E, et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006; 20:445-450.
63. Friis-Møller N, Sabin CA, Weber R, et al. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
64. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77. (Pubitemid 47514615)
65. Duval X, Baron G, Garelik D, et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther 2008; 13:389-397. (Pubitemid 352016732)
66. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study. J Stud Alcohol 2002; 63:179-186. (Pubitemid 34533593)
67. Lampe FC, Smith CJ, Madge S, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167:692-700.
68. Murray M, Hogg RS, Lima VD, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 2012; 13:89-97.
69. Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011; 6:e22698.
70. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011; 6:478-482.
71. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts-16th International AIDS Conference epidemiology plenary. Clin Infect Dis 2007; 44:981-987. (Pubitemid 46452067)
72. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord; Lewden C, Bouteloup V, DeWit S, et al. All-cause mortality in treated HIV-infected adults with CD4-500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41:433-445.
73. Rodger A, Lodwick R, Schechter M, et al. Mortality in patients with well controlled HIV and high CD4 counts in the cART arms of the SMART and ESPIRIT randomized clinical trials compared to the general population. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle. 2012. Poster #638.
74. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per mu L in Europe and North America: a pooled cohort observational study. Lancet 2010; 376:340-345.
75. Gebo KA. HIV and aging-implications for patient management. Drugs Aging 2006; 23:897-913.